Azimuth Capital Investment Management’s AstraZeneca AZN Stock Holding History

Azimuth Capital Investment Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.9M	Sell	57,300 -1,245	-2%	-$234K	0.37%	89
2026 Q1	$11.5M	Buy	58,545 +310	+0.5%	+$59.8K	0.43%	80
2025 Q4	$10.7M	Buy	58,235 +97	+0.2%	+$17K	0.38%	88
2025 Q3	$8.92M	Buy	58,138 +650	+1%	+$98.4K	0.32%	108
2025 Q2	$8.03M	Buy	57,488 +2,505	+5%	+$351K	0.3%	120
2025 Q1	$8.08M	Sell	54,983 -4,805	-8%	-$695K	0.32%	117
2024 Q4	$7.83M	Buy	59,788 +34,503	+136%	+$4.83M	0.3%	108
2024 Q3	$3.94M	Buy	+25,285	New	+$4.08M	0.15%	160
2023 Q3	–	Sell	-31,910	Closed	-$4.57M	–	292
2023 Q2	$4.57M	Sell	31,910 -688	-2%	-$101K	0.22%	144
2023 Q1	$4.53M	Sell	32,598 -742	-2%	-$99.8K	0.22%	146
2022 Q4	$4.52M	Sell	33,340 -778	-2%	-$97.6K	0.23%	142
2022 Q3	$3.74M	Sell	34,118 -1,365	-4%	-$173K	0.2%	155
2022 Q2	$4.69M	Buy	+35,483	New	+$4.66M	0.24%	140

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Azimuth Capital Investment Management's AZN Position: Q2 2026 in Review

Azimuth Capital Investment Management reduced its AstraZeneca (AZN) stake by 2.1% in Q2 2026, selling an estimated $234K and leaving 57,300 shares worth $10.9M. The position accounts for 0.37% of the portfolio, ranked #89.

Azimuth Capital Investment Management first reported a position in AZN in Q2 2022 and has held it in 13 quarters since. The position peaked at $11.5M in Q1 2026. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Azimuth Capital Investment Management held 57,300 shares of AstraZeneca worth $10.9M as of Q2 2026.
Azimuth Capital Investment Management sold 1,245 AstraZeneca shares in Q2 2026, an estimated $234K.
AstraZeneca made up 0.37% of Azimuth Capital Investment Management's portfolio in Q2 2026, its #89 holding.
Azimuth Capital Investment Management first reported a position in AstraZeneca in Q2 2022 and has held it in 13 quarters since.
Azimuth Capital Investment Management's AstraZeneca position peaked at $11.5M in Q1 2026.
1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Azimuth Capital Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.